Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dimension Therapeutics Inc.

www.dimensiontx.com

Latest From Dimension Therapeutics Inc.

Deals Shaping The Medical Industry, September 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Deals Medical Device

Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie

French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.

Deals M & A

Appointments: G1 Therapeutics, Breath Therapeutics, Fortress Biotech, Freeline Therapeutics, Enterome and Symic Bio

GSK's former CEO Sir Andrew Witty has joined the board of directors of the oncology company, G1 Therapeutics. This week's roundup also includes CEO appointments by Fortress Biotech, Freeline Therapeutics and BridgeSat, in addition to various other high-level appointments by Nabriva Therapeutics, Caribou Biosciences, Symic Bio and Breath Therapeutics.

BioPharmaceutical Appointments

Nestlé's Microbiome Interest Deepens With Enterome JV

Nestlé Health Science has invested $23m in a joint venture it is setting up with French microbiome company Enterome. Microbiome Diagnostics Partners (MDP) will be focused on developing microbiome-based diagnostics for the assessment and management of irritable bowel disorder and liver diseases.

Gastrointestinal Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Dimension Therapeutics Inc.
  • Senior Management
  • Annalisa Jenkins, CEO
    Sam Wadsworth, PhD, CSO
    Andy Hu, MD, Head, Bus. Dev.
    Mary Thistle, COO
    K. Reed Clark, PhD, SVP, Head, Pharmaceutical Dev.
    Eric Crombez, MD, CMO
    Alex Fotopoulos, MSc, SVP, Head Tech Ops.
    Deborah Geraghty, PhD, SVP, Head Corp Strategy
    Robert Gaffey, VP, Finance
    Janet Rae, Head, Global Reg Affairs
    Khandan Baradaran, PhD, Head of Quality
  • Contact Info
  • Dimension Therapeutics Inc.
    Phone: (617) 401-0011
    840 Memorial Dr.
    4th Fl.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register